[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-357725-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-357725-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","biomarkers-for-predicting-and-monitoring-the-efficacy-of-cancer-vaccines","Biomarkers for predicting and monitoring the efficacy of cancer vaccines","","Therapeutic cancer vaccines represent a modern, personalized anti-tumor strategy that relies on stimulating the patient’s immune system to recognize and eliminate malignant cells. The review addresses a major barrier to clinical translation: the absence of reproducible biomarkers for predicting and monitoring vaccine efficacy. It summarizes efficacy biomarkers and assessment methods used across clinical and preclinical tumor vaccine trials, focusing on common immune-monitoring approaches such as ELISA and flow cytometry, and analyzes challenges for real-world implementation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/biomarkers-for-predicting-and-monitoring-the-efficacy-of-cancer-vaccines/357725/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/biomarkers-for-predicting-and-monitoring-the-efficacy-of-cancer-vaccines/357725.png","ImageObject",300,407,{"name":42,"@type":43},"awa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are reproducible biomarkers important for cancer vaccine therapy?","Question",{"text":63,"@type":64},"Widespread clinical use is hindered by the lack of reproducible biomarkers that can evaluate and predict vaccine efficacy in routine settings.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which methods are commonly used to assess patients’ immune status in vaccine studies?",{"text":68,"@type":64},"ELISA and flow cytometry are commonly used to assess activation of the patient’s immune system.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the review’s focus regarding biomarkers?",{"text":72,"@type":64},"It describes efficacy biomarkers and evaluation methods used in multiple tumor vaccine clinical and preclinical trials and discusses challenges for applying them in real-world clinical practice.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},357725,1791017405,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","TYPE Review  \nPUBLISHED 24 July 2026  \nDOI 10.3389/fonc.2026.1904586  \nOPEN ACCESS  \nEDITED BY  \nLaura Conti,  \nUniversity of Turin, Italy  \nREVIEWED BY  \nGiandomenico Roviello,  \nUniversity of Firenze, Italy Mohadeseh Haji Abdolvahab, ACECR Tehran University of Medical Sciences Organization, Iran  \n*CORRESPONDENCE  \nAnastasia G. Volkova  \n [avolkova@cspfmba. ru](avolkova@cspfmba. ru)  \n†These authors have contributed equally to this work  \nRECEIVED 09 June 2026  \nREVISED 09 July 2026  \nACCEPTED 10 July 2026  \nPUBLISHED 24 July 2026  \nCITATION  \nRemizova JA, Volkova AG, Makarova AS,  \nMakarov VV, Yudin VS and Keskinov AA (2026) Biomarkers for predicting and monitoring the efﬁcacy of cancer vaccines.  \nFront. Oncol. 16:1904586 .  \ndoi: 10.3389/fonc.2026.1904586  \nCOPYRIGHT  \n© 2026 Remizova, Volkova, Makarova, Makarov, Yudin and Keskinov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nBiomarkers for predicting and monitoring the efﬁcacy of cancer vaccines  \nJulia A. Remizova †, Anastasia G. Volkova*†, Anna S. Makarova, Valentin V. Makarov, Vladimir S. Yudin and Anton A. Keskinov  \nFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency, Moscow, Russia  \nCancer vaccines are a modern approach to personalized anti-tumor therapy for malignant neoplasms based on stimulating the patient’s immune system to target tumor cells. Many studies have demonstrated the impressive efﬁcacy of antitumor vaccines in treating patients with different localization, type and stage of neoplasm. One of the major obstacles to the widespread implementation of cancer vaccines into clinical practice is the lack of reproducible biomarkers to evaluate and predict the efﬁcacy of tumor vaccine therapy. The most commonly used methods for assessing a patient ’s immune status are ELISA and ﬂow cytometry, which make it possible to assess the activation of the patient ’s immune system. However, multiple clinical trials have not yet demonstrated the reproducibility of these study results. This review includes description of efﬁcacy biomarkers and methods for their evaluation used in a number of tumor vaccines’clinical and preclinical trials, and discuss the challenges of applying the biomarkers in real-world clinical practice.  \nKEYWORDS  \nbiomarkers, cancer vaccines, cell-based vaccines, DNA vaccines, immunotherapy, malignant neoplasm, mRNA vaccines, peptide vaccines  \nIntroduction: therapeutic anti-tumor vaccines and immunity  \nImmuno-oncology research has helped expand the possibilities to apply immunotherapeutic strategies in the treatment of malignant neoplasms (MN) . Immunotherapy of malignant neoplasms is aimed at activating and enhancing the body’s natural anti-tumor immune response. This involves inﬁltration of the tumor and tumor microenvironment (TME) by cells of the adaptive (B-and T-cells) and innate (natural killer cells, eosinophils, basophils, mast cells, neutrophils, monocytes, macrophages and dendritic cells) immune systems, which leads to modulation of tumor progression (1–4) . Tumor cells have several escape mechanisms from immune surveillance, such as defects in the antigen (Ag) presentation system and the recruitment of immunosuppressive cell populations (5–7) . Taking into account the incomplete knowledge about the processes occurring at different stages of immunotherapy, this limits its possible widespread use in clinical practice.  \nAs a promising approach in immunotherapy, therapeutic anti-tumor vaccines are capable of overcoming insufﬁcient tumor","cbCaiovIzHsgAN5u","https://ap.wps.com/l/cbCaiovIzHsgAN5u","pdf",772192,15,"English","# Introduction: therapeutic anti-tumor vaccines and immunity\n## Immuno-oncology background and immune escape\n## Therapeutic vaccine targeting: TAA versus TSA\n## Development challenges for personalized vaccines","[{\"question\":\"Why are reproducible biomarkers important for cancer vaccine therapy?\",\"answer\":\"Widespread clinical use is hindered by the lack of reproducible biomarkers that can evaluate and predict vaccine efficacy in routine settings.\"},{\"question\":\"Which methods are commonly used to assess patients’ immune status in vaccine studies?\",\"answer\":\"ELISA and flow cytometry are commonly used to assess activation of the patient’s immune system.\"},{\"question\":\"What is the review’s focus regarding biomarkers?\",\"answer\":\"It describes efficacy biomarkers and evaluation methods used in multiple tumor vaccine clinical and preclinical trials and discusses challenges for applying them in real-world clinical practice.\"}]","Biomarkers for predicting and monitoring the efficacy of cancer vaccines | PDF",1790131548,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cb91c4357d8c5d2bcbdf3c1aa244628.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4250ab599eafb5cb2302182f1d758794.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b033dfbb6c2f8e510042177961f26a79.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af05a2216db9cf384c4c16df7691818a.webp",980,1385]